Antibody-conjugated lipid nanoparticles to enhance extrahepatic nucleic acid delivery

Introduction: Lipid nanoparticles (LNPs) have become important carriers for nucleic acid across a spectrum of therapeutic applications, including vaccines, gene editing, and cancer immunotherapy. Despite their widespread utilities, LNPs mainly accumulate in the liver following systemic administration, thereby limiting their therapeutical applications. To address these issues, this study demonstrates an active targeting strategy to enhance extrahepatic tropism by tethering antibodies to the LNPs.